Exploratory research of Expression of Acrolein and Vascular Adhesion Protein-1 (VAP-1) in Diabetic Retinopathy

Exploratory research of Expression of Acrolein and Vascular Adhesion Protein-1 (VAP-1) in Diabetic Retinopathy - Acrolein and VAP-1 in Diabetic Retinopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019729

Enrollment

Registered

2015-11-10

Start date

2015-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with proliferative diabetic retinopathy (Study group) 2. Patients with idiopathic macular hole or epiretinal membrane (Control group) 3.Patients who had a detailed briefing of the study with explanatory documents prior to the enrollment and voluntarily signed a consent form

Exclusion criteria

Exclusion criteria: 1. Patients with vitreous hemorrhage due to proliferative diabetic retinopathy 2. Patients with diabetes in control group 3.Patients who investigator considered inappropriate as a subject of this study

Design outcomes

Primary

Measure	Time frame
Concentrations of acrolein and soluble VAP-1 in the vitreous and serum samples obtained from patients with diabetic retinopathy	—

Countries

Japan

Contacts

Public ContactKousuke Noda

Hokkaido University Graduate School of Medicine Department of Ophthalmology

nodako@med.hokudai.ac.jp011-706-5944

Outcome results